“中国临床试验反超”，美媒焦虑：药也都要中国制造了

Core Insights - China's rise in biotechnology is prompting the U.S. to catch up, as evidenced by significant increases in clinical trial registrations and laboratory construction [1][3][7] - In 2024, China is expected to register over 7,100 clinical trials, surpassing the U.S. with approximately 6,000 [1] - The area of laboratories and R&D centers under construction in Beijing and Shanghai is significantly larger than in other global markets, with 740 million square feet and 640 million square feet respectively [1][3] Clinical Trials and R&D - China has overtaken the U.S. in the number of ongoing clinical trials, with a reported increase of 379% in pharmaceutical and medical technology patents since 2014 [3][5] - The shift from imitation to original drug development in China is attracting more licensing agreements and investments from major pharmaceutical companies [5][6] Investment Trends - An estimated 37% of licensed drugs from large pharmaceutical companies are projected to come from China this year, up from 12% in previous years [5][6] - The emergence of successful Chinese biotech firms, such as BeiGene, is drawing attention from international investors [6][7] U.S. Response and Concerns - U.S. politicians are increasingly concerned about China's advancements in biotechnology, with calls for increased investment to maintain leadership in the sector [7][8] - Experts warn that cuts to U.S. biomedical research funding could further hinder American competitiveness in drug development [8]